Updated:
Scripps Research Institute
Scripps Research Institute was founded in 1924 by Ellen Browning Scripps as a nonprofit medical research facility. Peter G. Schultz serves as president and...
Scripps Research Institute
Scripps Research Institute was founded in 1924 by Ellen Browning Scripps as a nonprofit medical research facility. Peter G. Schultz serves as president and CEO. The organization operates graduate training programs and drug development arms including Calibr. The institute allocates across private equity, venture capital, and real estate. Confirmed holdings include Protego Biopharma, Blackthorn Therapeutics, and Uvax Bio. It maintains positions in the United States and has executed exits such as Vividion Therapeutics. Geographic reach covers California research sites and prior Florida operations now integrated with University of Florida. Assets total 541 million dollars with 2100 employees. Additional offices are absent after the 2022 campus transfer. Adjacent vehicles include the Scripps Research Translational Institute established in 2007 and the Calibr-Skaggs Institute for Innovative Medicines. May 2024 marked the opening of the Chi-Huey Wong Laboratories facility on the La Jolla campus. The structure separates research operations from investment management through an external OCIO relationship with Strategic Investment Group. Board oversight rests with John D. Diekman and Thomas Daniel. This setup channels royalty income from over 1100 patents directly into laboratory construction and spin-off formation.
General information
Firm type
Endowment / Foundation
Year founded
1924
Location
Region
North America
Country
United States
City
La Jolla
Corporate office
10550 North Torrey Pines Road, La Jolla, CA 92037, United States
Principals
Peter G. Schultz
President and CEO
John D. Diekman
Chairman of the Board
Sector focus
Frequently asked questions
Who runs investment decisions at Scripps Research Institute?
Peter G. Schultz serves as president and CEO. External managers including Portfolio Advisors and HarbourVest Partners handle portfolio allocation under board supervision.
Does Scripps Research Institute participate in fund commitments or only direct deals?
The institute holds both fund interests such as Varde Private Debt Opportunities Fund and direct ownership in biotechnology startups including Protego Biopharma and Uvax Bio.
What investment stages does Scripps Research Institute typically target?
Activity focuses on early-stage biotechnology companies and seed through expansion rounds. Exits have included Vividion Therapeutics and Abide Therapeutics.
Where does the underlying wealth come from?
Ellen Browning Scripps established the original clinic in 1924. Ongoing revenue derives from patent royalties and licensing agreements with pharmaceutical partners.
How is Scripps Research Institute related to its spin-off companies?
Faculty members including Benjamin Cravatt and Paul Schimmel founded multiple portfolio companies. Ownership passes through the institute or affiliated entities such as Calibr.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: